This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/drugbank/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/national-drug-code-directory/
n11http://www.rxlist.com/cgi/generic/
n13http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/genbank/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/uniprotkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00068/identifier/pharmgkb/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00068
rdf:type
n6:Drug
n6:description
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
n6:dosage
n16:271B432D-363D-11E5-9242-09173F13E4C5 n16:271B432E-363D-11E5-9242-09173F13E4C5
n6:group
approved
n6:indication
Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
owl:sameAs
n15:DB00068 n20:DB00068
dcterms:title
Interferon beta-1b
adms:identifier
n4:50419-523-35 n5:V00534 n8:C07901 n21:DB00068 n22:Interferon_beta-1b n23:PA450039 n27:P01574 n28:D00746
n6:mechanismOfAction
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
n6:packager
n17:271B4329-363D-11E5-9242-09173F13E4C5 n17:271B4327-363D-11E5-9242-09173F13E4C5 n17:271B4328-363D-11E5-9242-09173F13E4C5 n17:271B4325-363D-11E5-9242-09173F13E4C5 n17:271B4326-363D-11E5-9242-09173F13E4C5
n6:patent
n13:1339707 n13:1340861
n6:synonym
Interferon beta precursor IFN-beta Fibroblast interferon
n6:volumeOfDistribution
* 0.25 to 2,88 L/kg
n6:synthesisReference
Heinz-Jurgen Friesen, Sidney Pestka, "Preparation of homogeneous human fibroblast interferon." U.S. Patent US4289689, issued December, 1968.
n24:hasConcept
n25:M0129586
foaf:page
n11:interferon_beta.htm n26:interferon-beta-1b-solution.html
n6:Molecular-Formula
n7:271B4332-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B4331-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:L03AB08
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
145155-23-3
n6:category
n6:clearance
* 9.4 – 28.9 mL/min•kg-1 [patients with diseases other than MS receiving single intravenous doses up to 2.0 mg]
n6:containedIn
n12:271B432A-363D-11E5-9242-09173F13E4C5 n12:271B432B-363D-11E5-9242-09173F13E4C5 n12:271B432C-363D-11E5-9242-09173F13E4C5
n6:Hydrophobicity
n7:271B432F-363D-11E5-9242-09173F13E4C5
n6:Isoelectric-Point
n7:271B4330-363D-11E5-9242-09173F13E4C5